Particularly, oncogenic activation of the PI3K/AKT/mTOR pathway can occur because of various mutations including overexpression of upstream regulators, PI3K catalytic subunit alpha (PI3KCA) mutation, and loss of phosphatase and tensin homolog (PTEN) in triple-negative breast cancer [6,7,8]. Here, PTEN is linked to triple-negative breast carcinoma.